Leerink analyst Joseph Schwartz downgraded Amicus (FOLD) to Market Perform from Outperform with a price target of $14.50, down from $17, following the recently announced acquisition by BioMarin (BMRN). The firm views BioMarin is a good strategic fit and thinks it is unlikely that another bid will emerge.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD: